Welcome to our dedicated page for Synopsys SEC filings (Ticker: SNPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synopsys, Inc. (SNPS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Synopsys common stock is registered on the Nasdaq Global Select Market, and the company regularly uses Form 8-K and other filings to report material events, financial results, and governance changes. These documents are central resources for understanding how Synopsys presents its business segments, strategic actions, and risk factors to investors.
Recent 8-K filings illustrate several themes that may be of interest to shareholders and analysts. One filing reports a restructuring plan approved by the board of directors, which is expected to affect approximately 10% of the workforce as of fiscal 2025 year-end. Synopsys states that this plan is intended to support investment in key growth opportunities and drive business efficiencies following the completion of its acquisition of Ansys, Inc., with substantial completion expected by the end of fiscal year 2027, subject to local requirements.
Other 8-Ks disclose topics such as the departure or appointment of certain officers, reaffirmation of financial targets, and the announcement of quarterly financial results. In its earnings-related filings and press releases, Synopsys reports revenue and net income on both GAAP and non-GAAP bases, provides reconciliations, and explains adjustments related to amortization of acquired intangible assets, stock-based compensation, acquisition and divestiture items, restructuring charges, and tax effects.
Filings also document regulatory and export control developments. For example, Synopsys reported receiving a letter from the U.S. Department of Commerce’s Bureau of Industry and Security rescinding previously imposed export restrictions related to China, and noted that it is working to restore access to affected products while assessing the impact of such restrictions on its business. Forward-looking statements sections in these filings outline risks and uncertainties related to macroeconomic conditions, industry trends, acquisitions, export controls, and other factors.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that highlight key items such as restructuring plans, segment disclosures, export control updates, and earnings metrics. This helps readers quickly identify the portions of Synopsys’ 8-Ks, 10-Ks, 10-Qs, and related filings that are most relevant to their analysis of SNPS.
Synopsys, Inc. reported an insider stock sale by its General Counsel and Corporate Secretary, Janet Lee. On 01/12/2026, she sold 250 shares of Synopsys common stock in an open market transaction coded "S" at a price of $530 per share. Following this sale, she directly holds 11,959 shares of Synopsys common stock. The filing lists her as an officer and shows no derivative securities transactions in this report.
An individual investor, Janet Lee, filed a Form 144 notice to sell 250 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The planned sale has an aggregate market value of $132,500, compared with 191,318,206 common shares outstanding. The 250 shares to be sold were acquired on July 18, 2025 as merger consideration from the issuer, with payment also dated July 18, 2025 and noted as not applicable for non-cash terms. During the past three months, Janet Lee has already sold 250 common shares for gross proceeds of $127,500.
Synopsys Inc.’s General Counsel and Corporate Secretary, Janet Lee, reported a small insider sale of company stock. On 01/07/2026, she sold 250 shares of Common Stock at a price of $510 per share, according to a Form 4 insider trading report.
After this transaction, Lee directly beneficially owns 12,209 Synopsys shares. The filing shows only this single, non-derivative stock sale and no derivative securities transactions.
A holder of common stock has filed a Rule 144 notice to sell 250 shares through Morgan Stanley Smith Barney LLC on or about 01/07/2026 on the NASDAQ market. The filing lists an aggregate market value of $127,500.00 for these shares, compared with 191,318,206 shares of the same class reported as outstanding. The seller originally acquired the 250 shares as merger consideration from the issuer on 07/18/2025, with the purchase price noted as not applicable, indicating no separate cash payment at that time.
Synopsys, Inc. files its annual report for the fiscal year ended October 31, 2025, outlining a business built around two segments: Design Automation and Design IP. The company positions itself as a leader in engineering solutions "from silicon to systems," with core strength in electronic design automation (EDA), silicon IP and simulation and analysis (S&A) software.
A key development is the acquisition of ANSYS, Inc., which adds a broad portfolio of multiphysics S&A tools to the Design Automation segment and helped increase total headcount by about 40% to roughly 28,000 employees. Synopsys now reports four revenue groups: EDA, Design IP, Ansys and Other, and highlights growing use of AI-driven tools through its Synopsys.ai stack across design, verification and manufacturing.
The report notes an aggregate market value of about $59.3 billion for non‑affiliate common equity as of the last business day of the most recent second fiscal quarter, and 191,318,206 common shares outstanding as of December 15, 2025. Synopsys also describes a new October 31 fiscal year-end, a global footprint of 189 offices, and emphasizes responsible business, human capital investment, and extensive use of forward‑looking statements around AI, the Ansys Merger, macroeconomic conditions and regulatory risks.
Synopsys Inc. reported an equity award for its Chief Financial Officer, Shelagh Glaser. The Compensation Committee granted her 7,554 restricted stock units under the Synopsys, Inc. 2006 Employee Equity Incentive Plan. These units have a conversion price of $0.0 and represent potential shares of common stock.
One-sixth of the units vest on 12/16/2025, with the remaining units vesting in five equal semi-annual installments through 12/15/2028, contingent on continued service. Following the grant, she holds 7,554 derivative securities directly.
Synopsys, Inc. reported an equity award for its Chief Accounting Officer, Sudhindra Kankanwadi. On 12/16/2025, he received a grant of 4,317 restricted stock units (RSUs) under the Synopsys, Inc. 2006 Employee Equity Incentive Plan. Each RSU represents a right to receive one share of Synopsys common stock for no cash exercise price.
According to the vesting schedule, one-sixth of the units vest on 06/15/2026, with the remaining units vesting in five equal semi-annual installments through 12/15/2028, as long as he continues to provide service to the company through each vesting date. This filing reflects a routine compensation-related grant rather than a market sale or purchase of shares.
Synopsys Inc reported an equity award to its Executive Chair and director, Aart de Geus. On 12/16/2025, he received 2,693 restricted stock units classified as derivative securities with an exercise price of $0.0, beneficially owned directly.
The grant was approved by the Compensation Committee under the Synopsys, Inc. 2006 Employee Equity Incentive Plan. One-sixth of the units vest on 06/15/2026, followed by five equal semi-annual installments, conditioned on continued service through each vesting date. The RSUs are scheduled to expire on 12/15/2028.
Synopsys, Inc. reported an equity award to one of its senior executives. On 12/16/2025, officer Janet Lee, who serves as GC & Corporate Secretary, received a grant of 3,238 restricted stock units under the Synopsys, Inc. 2006 Employee Equity Incentive Plan. Each unit represents a right to receive one share of Synopsys common stock for no cash exercise price.
According to the vesting terms, one-sixth of the units vest on 06/15/2026, with the remaining units vesting in five equal semi-annual installments through 12/15/2028, subject to continued service. The award is reported as directly owned and is a routine part of executive equity compensation, not an open-market stock sale or purchase.
Synopsys, Inc. reported that Chief Revenue Officer Michael Ellow received a grant of 24,286 restricted stock units on December 12, 2025. Each unit represents the right to receive one share of Synopsys common stock for no cash payment.
The grant was approved by the Compensation Committee under the Synopsys, Inc. 2006 Employee Equity Incentive Plan. One-sixth of the units vest on June 15, 2026, with the remaining units vesting in five equal semi-annual installments through December 15, 2028, subject to Mr. Ellow’s continued service.